Resveratrol inhibits IL-6-induced transcriptional activity of AR and STAT3 in human prostate cancer LNCaP-FGC cells

Biomolecules and Therapeutics

Volumn 22, Issue 5, 2014, Pages 426-430

  Lee, Mee Hyun ^a,b   Kundu, Joydeb Kumar ^c   Keum, Young Sam ^d   Cho, Yong Yeon ^b   Surh, Young Joon ^a   Choi, Bu Young ^e  

^a Seoul National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Keimyung University   (South Korea)

^d Dongguk University   (South Korea)

^e Seowon University   (South Korea)

Author keywords

AR transcriptional activity; Prostate cancer; Resveratrol; STAT3 transcriptional activity

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; INTERLEUKIN 6; RESVERATROL; STAT3 PROTEIN;

AR GENE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE ACTIVITY; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; REPORTER GENE; STAT3 GENE; TRANSCRIPTION INITIATION;

EID: 84908018839     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2014.061     Document Type: Article

References (20)

1. Bommareddy, A., Eggleston, W., Prelewicz, S., Antal, A., Witczak, Z., McCune, D. F. and Vanwert, A. L. (2013) Chemoprevention of prostate cancer by major dietary phytochemicals. Anticancer Res. 33, 4163-4174.
2. Chun, J. Y., Nadiminty, N., Dutt, S., Lou, W., Yang, J. C., Kung, H. J., Evans, C. P. and Gao, A. C. (2009) Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin. Cancer Res. 15, 4815-4822.
3. Guo, Y., Xu, F., Lu, T., Duan, Z. and Zhang, Z. (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38, 904-910.
4. Ha, S., Iqbal, N. J., Mita, P., Ruoff, R., Gerald, W. L., Lepor, H., Taneja, S. S., Lee, P., Melamed, J., Garabedian, M. J. and Logan, S. K. (2013) Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene 32, 3992-4000.
5. Harada, N., Atarashi, K., Murata, Y., Yamaji, R., Nakano, Y. and Inui, H. (2011) Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: Implication of DNA binding and acetylation of the receptor. J. Steroid Biochem. Mol. Biol. 123, 65-70.
6. Harada, N., Murata, Y., Yamaji, R., Miura, T., Inui, H. and Nakano, Y. (2007) Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J. Nutr. Sci. Vitaminol. (Tokyo) 53, 556-560.
7. Kai, L. and Levenson, A. S. (2011) Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells. Anticancer Res. 31, 3323-3330.
8. Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., Carter, B., Turkson, J. and Jove, R. (2006) Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 5, 621-629.
9. Kundu, J. K. and Surh, Y. J. (2008) Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 269, 243-261.
10. Laufer, M., Denmeade, S. R., Sinibaldi, V. J., Carducci, M. A. and Eisenberger, M. A. (2000) Complete androgen blockade for prostate cancer: what went wrong? J. Urol. 164, 3-9.
11. Mitchell, S. H., Zhu, W. and Young, C. Y. (1999) Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 59, 5892-5895.
12. Narayanan, B. A., Narayanan, N. K., Re, G. G. and Nixon, D. W. (2003) Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int. J. Cancer 104, 204-212.
13. Ratan, H. L., Steward, W. P., Gescher, A. J. and Mellon, J. K. (2002) Resveratrol--a prostate cancer chemopreventive agent? Urol. Oncol. 7, 223-227.
14. Shankar, S., Singh, G. and Srivastava, R. K. (2007) Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front. Biosci. 12, 4839-4854.
15. Shi, W. F., Leong, M., Cho, E., Farrell, J., Chen, H. C., Tian, J. and Zhang, D. (2009) Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One 4, e7398.
16. Siegel, R., Ma, J., Zou, Z. and Jemal, A. (2014) Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29.
17. van der Poel, H. G., Zevenhoven, J. and Bergman, A. M. (2010) Pim1 regulates androgen-dependent survival signaling in prostate cancer cells. Urol. Int. 84, 212-220.
18. Walsh, P. C., DeWeese, T. L. and Eisenberger, M. A. (2007). Clinical practice. Localized prostate cancer. N. Engl. J. Med. 357, 2696-2705.
19. Wang, Z., Fan, J., Liu, M., Yeung, S., Chang, A., Chow, M. S., Pon, D. and Huang, Y. (2013) Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application. Expert Opin. Investig. Drugs 22, 1613-1626.
20. Zemskova, M., Sahakian, E., Bashkirova, S. and Lilly, M. (2008) The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J. Biol. Chem. 283, 20635-20644.